2024 CWISummit Frankenplating
Moderator: Kurt A. Martinson, MD, FACS
Coordinator: Indraneel Brahme, MD

This session will include examples of innovation and/or controversy, where creativity and experience helped improve individual patient outcomes.
A "Frankenplating" example is probably along the lines of "it's crazy enough it just might work"!
Cases were submitted to and selected by the CWISummit Program Committee.
DISCLAIMER: Good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement. If physicians use a product for an indication not in the approved labeling, they have the responsibility to be well informed about the product, to base its use on firm scientific rationale and on sound medical evidence, and to maintain records of the product's use and effects. Use of a marketed product in this manner when the intent is the "practice of medicine" does not require the submission of an Investigational New Drug Application (IND), Investigational Device Exemption (IDE) or review by an Institutional Review Board (IRB). However, the institution at which the product will be used may, under its own authority, require IRB review or other institutional oversight.
The Chest Wall Injury Society does not endorse nor promote the use of products outside of approved clinical indication. Any clinical decisions are the sole responsibility of the respective healthcare professionals.